Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
. Local disease is often curable by radiation or surgery; however, patients with advanced (metastatic) disease are treated by androgen deprivation therapy (ADT) that ablates testicular androgen synthesis that is needed for continued tumor growth (2) . Unfortunately, ADT is usually only palliative since the tumor often recurs in a state that is refractory to the low systemic androgen levels in ADT-treated patients. This phenotype, termed castrate resistant PCa (CRPC), is the main cause of mortality from the disease. Recently, we learned that progression to CRPC can be linked to acquired intratumoral steroidogenesis (IS) that supports renewed activity of the androgen receptor (AR) in tumor cells thus enabling tumor re-growth (3) . While new generation of drugs (abiraterone [abi] or Enzalutamide) that target IS or renewed AR activity have shown the ability to increase survival of CRPC patients (4) , most patients treated with these drugs also soon develop resistance that limits the drug's effectiveness. Resistance to the new generation drugs is thought to be due to adaptions of the tumor cells themselves that further increase IS (5) . This hypothesis, though, neglects any potential contributions to IS of cancer-adjacent stromal cells that might also acquire a steroidogenic phenotype upon exposure to the Hedgehog (Hh) signaling microenvironment of an androgen deprived prostate tumor (6 
OVERALL PROJECT SUMMARY:
3a. Brief overview of the Clinical Problem Addressed by the Project: In adult males, the normal functioning of the prostate is dependent on interactions with the surrounding stromal environment, much as the development of the prostate gland is dependent on the stromal mesenchyme for proper form and function. In cancers, these interactions are interfered with, disrupting homeostasis, differentiation, and growth; sometimes evoking tumor inhibition, at other times enhancing tumor progression (7) . Recent studies from our laboratory have shown that, under androgen deprived conditions, PCa cells upregulate and secrete large amounts of Sonic Hedgehog ligand (Shh), which interacts with its receptor Patched-1 (Ptch-1) on the stromal cells to initiate a signaling chain through de-repression of Smoothened (Smo) and activation of Gli2 transcription factor signaling which culminates in the activation and secretion of steroidogenic enzymes and steroids, respectively (6) . These steroids can feed back to the tumor cells, which, after ADT, have hypersensitive AR (8) . Stromal steroidogenesis may play a significant part in the steroid milieu of the tumor microenvironment in addition to ADT driven upregulation of the steroidogenic potential of tumor cells, which are able to synthesize steroids from adrenal precursors, such as Dehydroepiandrosterone (DHEA), or de novo from precursors such as cholesterol or acetate through either the classical steroidogenesis pathway, or the backdoor pathway, which bypasses testosterone (T) as an intermediate for dihydrotestosterone (DHT) (3, (9) (10) (11) .
After ADT, recurrence occurs in the majority of patients (8) , and often progresses to metastatic disease. For PCa, the most common site for metastasis is bone, and these metastases are a major cause of morbidity due to replacement of haematopoietic tissue with tumor and decreased bone stability (12) . Bone overgrowth at metastatic sites causes pain, fracture and spinal cord compression in patients. It has already been demonstrated that bone mesenchymal cells can be differentiated into steroidogenic cells (13) by overexpression of steroidogenic factor-1 (SF), and that SF-1 is a Hh target gene in Leydig cell differentiation (14) . Furthermore, enzymes for androgen production are highly expressed in bone core metastases samples (15 . This is an important finding in consideration that, in the developing leydig cells, once steroidogenesis is initiated, it no longer requires ligand (17) . Therefore, the Hh pathway is a feasible target for decreasing steroidogenesis in PCa. Furthermore, we have discovered that, on a per cell basis, PrSC in the presence and absence of Hh agonist are generally equal to some of the most common PCa cell lines (LNCaP and 22RV1) in steroid output when fed 22-OH cholesterol, a precursor for de novo steroidogenesis; however, especially under the influence of Ag1.5, PrSC cells produce much more pregnenolone, the first steroid in the steroidogenesis pathway (Figure 2a ). This leads us to hypothesize that pregnenolone from the Hh activated stroma may be used as a precursor for steroidogenesis in tumor cells, or that secreted steroids may be "traded" between stromal and epithelial cells. Likewise, PrSC cells produce a much greater amount of the steroids in the backdoor pathway, such as androsterone, especially with the addition of Ag1.5 ( Figure 2b ). We have also demonstrated much higher levels of T are produced by coculturing LNSHH cells than with parental LNCaPs or by either cell line alone when fed 30uM OH-cholesterol ( Figure 3 ). As LC/MS experiments are economically prohibitive, these are experiments optimized in the singular, then repeated for triplicates. . A recent publication from these same tumours showed that Tak441 only effects signalling in the surrounding stromal, and not tumour cell signaling, and inhibits tumour growth (18) . Taken together, these results demonstrate that Hh signalling between PCa and stromal cells is crucial to tumour steroidogenesis and may be an attractive therapeutic target in both local and metastatic PCa.
3b2. Simvastatin Blocks Paracrine Hedgehog Induced Prostate Stromal Cell Steroidogenesis via Multiple Avenues
Because the Shh ligand is highly lipid modified in order to be functional, requiring a cholesterol moiety for auto-catalytic cleavage to its active form, as well as a palmitoyl addition (19, 20) , we investigated whether simvastatin, which blocks the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) and therefore the rate limiting step for cholesterol synthesis, would inhibit steroidogenesis by interfering with the autocatalysis of Shh necessary for activation and secretion. We discovered, by ELISA, that simvastatin appears to increase output of Shh; however, simvastatin still prevents an increase in PrSC steroidogenesis when used in mock-co-culture (serum free medium is added to LNSHH or parental cells and let incubate in the presence or absence of 5µM 
3b3. The Stromal Contribution to the Development of Resistance to New Generation Drugs by Castration Resistant Prostate Cancers-Data Obtained so Far
We began our experiments by purchasing commercially available bone marrow stromal cells (BMS) (Stemcell Technologies, cat# MSC-001F), which are most often used to propagate and investigate mesenchymal stem cells. For our purposes, we attempted to maintain them as BMS cells. Under therecommended conditions of 10% FBS in DMEM, these cells grew very slowly, hindering our experimental abilities. We were able to complete two key experiments with these cells. Firstly, we investigated the effect of increasing dosages (50, 100, 200nM) of SAG Hh agonist on steroidogenesis enzyme mRNA after 48hrs (Figure 6a ). At 48hrs, all 3 concentrations significantly upregulated Gli1 signaling, which is the transcriptional regulator most often associated with active Hh signaling(24); however, only at 200nM SAG did we see significant upregulation of Gli2, the transcriptional regulator on which we have demonstrated prostate stromal cell (PrSC) steroidogenesis to depend (6) . We also demonstrated, by QRT PCR, significant upregulation of key steroidogenesis transcription factors SF-1 (2.6-fold, p<0.05), SREBP ( Figure 6b) ; SAG and Ag1.5 induced 72 and 20-fold increases in 4-pregnen-17-ol-3,20-dione (backdoor pathway), respectively, 20 and 2-fold increase in DHEA, and only SAG produced a 5.5-fold increase in T output . As treatment with 100nM SAG unexpectedly gave much higher increases in steroid output, we are in the process of determining the stability of our Ag1.5 stock. Following the cessation of experiments with commercially available BMS cells, we undertook the lengthy process of obtaining primary bone marrow stromal cells established by our collaborator and co-mentor, Dr. Eva Corey (25) (University of Washington), dubbed BMS-EC. We allowed cells to come to 70% confluence before starving in serum free medium for 48hrs. We then treated the cells with 1nM Ag1.5 for 48hrs, and observed mRNA increases in SF-1 (1.65-fold), SREBP (1.9-fold), CYP17A1 (2.6-fold), HSD3B2 (6.8-fold), AKR1C3 (3.55-fold), and HSD17B3 (3.9-fold), with increases of Gli1 and Gli2, 2.9 and 2.5-fold, respectively. Additionally, treatment with either 1nM Ag1.5 or 100nM SAG resulted in increased steroid output after 48hs treatment, with OHpregnenolone precursor. The highest outputs with Ag1.5 treatment were DHEA and androstenedione, 6.5 and 3.2-fold, respectively. Treatment with SAG increased outputs of pregnenolone (2.2-fold), progesterone (2.5-fold), 17-OH progesterone (2-fold), androstenedione (3.9-fold), T (2-fold), and androsterone (4.7-fold). Taken together, these results suggest that both commercially available BMS cells and BMS-EC cells are capable of de novo steroidogenesis when stimulated with Hh pathway agonists, and that this paracrine interaction with PCa cells may contribute to the favorable conditions for bone metastasis growth, making the interaction a promising target for therapeutic intervention. We propose that a transient PCa stem-like cell mediates these transdifferentiations. We sought to reveal/maintain this stem-like state using a special "stemtransition medium" that could give rise to these complex lineages from LNCaP, CWR22r1, LAPC4, or VCaP cells after at least 14days. The medium converted these cells, en masse, to small, rounded proliferating cells that grew as 3D rosettes and spheroids. QRT and CD antigen profiling of converted LNCaP cells were most consistent with a neural/neural crest stem-like (N/NCSL) identity. N/NCSL cells fail to express androgen receptor (AR) or PSA and are significantly more resistant to hypoxia and enzalutamide than parental LNCaPs. The similarities and differences between the afore mentioned parental and stem-like cell lines were compared using microarray analysis and were found to be enriched for many of the same neural, stem-like, and developmental pathways.
A B
Androgen-free differentiation medium allowed LNCaP N/NCSL cells to express biomarkers of neuron-, glia-, oligodendrocyte or osteocyte-like cells. Following redifferentiation in androgencontaining medium, they reverted to epithelial cells resembling parental LNCaPs but they overexpressed AR and retained expression of nestin, a neural stem marker. LNCaP-N/NCSL cells have significantly increased tumor-initiating capability, forming tumors in nude mice from only 100 xenografted cells vs 10 6 parental cells, and are metastatic when injected intra-prostaticly. They are invasive in zebrafish where we observed cells metastasizing to the brain and spine, whereas parental LNCaPs remain in the yolk sac. Likewise, when injected in the neural crest area of developing chicken embryos, only LNCaP-NCSLs migrate throughout the neural tube. Lastly, the neural crest marker BRN3A is upregulated in our stem model and immunostaining shows that increased staining is strongly correlated with patient recurrence and inversely correlated with survival. In summary, we show that PCa(AR+) cells have a previously unsuspected developmental plasticity allowing them to revert to neural/neural crest stem-like state which may be correlated to PCa progression, therapy resistance and metastasis.
KEY RESEARCH ACCOMPLISHMENTS:
 Have determined that treatment of BMS cells with Hh agonists upregulates mRNA for key steroidogenesis enzymes in both the classical and backdoor pathways, in 2 different BMS cell lines.  Have shown that treatment of two BMS cell lines with Hh agonists increases secretion of steroids in both the classical and backdoor pathways.  Have established a co-culture system with LNCaP and LNSHH cells with PrSC which is likely easily adapted to BMS-EC.
CONCLUSION:
Our work has confirmed the importance of paracrine Hh signaling in PCa, as it actives/ upregulates steroidogenesis in PrSC and BMS cells. We have demonstrated that exposure to Hh agonists upregulates key steroidogenesis enzyme mRNAs present in both the classical and backdoor pathways and also increase production and secretion of steroids and androgens. We have demonstrated that these benign stromal cells, when activated by Hh, readily convert very upstream precursors OH-cholesterol and OH-pregnenolone to active steroids and androgens, signifying the capacity to contribute to de novo steroidogenesis. In PrSC cells, upregulation of pregnenolone synthesis was most notable; however, in commercially available BMS cells, the steroid with the highest increase in output was 4-pregnen-17-ol-3,20-dione, which is a key metabolite of the backdoor pathway. In all of the stromal cell lines, we have seen upregulation of GLi2, which we had previously demonstrated to be necessary for Hh mediated steroidogenesis (6) . Importantly, we have demonstrated that blocking the stromal steroidogenesis pathways in murine tumors can inhibit T and DHT production and slow tumor growth rate (18) . We have also demonstrated that Simvastatin may be a useful inhibitor of these pathways, in the context of PrSC.
Collectively, our work strongly supports that Hh signaling is involved in the progression of PCa to CRPC, at which time cells become refractory to androgen ablation by synthesizing their own
